Compare Summit Therapeutics Inc (SMMT) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Visa Inc — how do they compare? Summit Therapeutics Inc trades at $14.57 (market cap $10.48B), while Visa Inc trades at $356.3 (market cap $685.71B). The key difference: Visa Inc is far larger — about 65.4× Summit Therapeutics Inc's market cap, and Visa Inc pays a 0.74% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | V | |
|---|---|---|
Market Cap | $10.48B | $685.71B |
Sector | Health | Financials |
52-Week High | $29.32 | $365.14 |
52-Week Low | $13.05 | $295.52 |
Enterprise Value | $9.90B | $696.30B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $396.70. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding expectations. Revenue reached $40 billion in 2025, and net income margin stands at 51.68%, reflecting robust profitability. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
Visa presents a favorable long-term investment opportunity due to its dominant market position, consistent earnings growth, and high profitability. Key risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional ownership increasing, the stock offers upside potential, though investors should monitor execution on AI initiatives and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
